2 
Page 17, lines 12 and 13, strike out “Secretary or Health, Educa- 
tion, and Welfare” and insert in lieu thereof “President”. 
Page 17, line 13, strike out “Secretary” and insert in lieu thereof 
“President”. . 
Page 17, line 15, strike out “in the fields of’ and insert in lieu thereof 
“in such fields as”. 
Page 19, line 16, strike “the risk to health and the environment” and 
insert in lieu thereof “such risks to health and the environment as 
may be”. 
Page 20, line 4, strike out “and” after the semicolon. 
Page 20, line 6, after “economic,” insert “environmental.”. 
Page 20, line 8, strike out “technology,” and insert in lieu thereof the 
following : 
technology, as well as the significance of lessons learned 
through recombinant DNA research and its allied science 
policy issues ; and 
Page 20, lines 11 through 14, insert the following new subparagraph : 
(C) a comprehensive assessment of the status and applica- 
tions, achieved or anticipated, of genetic manipulation tech- 
nology in other nations engaged in such activities. 
Page 20, line 25, strike out “Secretary” and insert in lieu thereof 
“Commission”. 
(Much of the factual information which follows is the same as that 
contained in Part I of this report, prepared by the Committee on 
Interstate and Foreign Commerce.) 
PURPOSE OP LEGISLATION 
The purpose of the legislation is to assure that all research and 
other activities involving recombinant DNA molecules are conducted 
in accordance with national safety standards designed to prevent the 
creation and escape of genetically modified organisms or viruses which 
could pose a threat to public health or the environment. At the same 
time, however, the use of recombinant DNA methods is recognized 
to be of exceptional value to science. Thus, an additional purpose of 
the legislation is to prevent the imposition of unnecessarily restrictive 
state and local requirements. 
At present, work in this area supported or conducted by the Na- 
tional Institutes of Health must be carried out in accordance with 
safety guidelines prepared and released by NIH. Most other Federal 
agencies have adopted the NIH Guidelines as agency policy. However, 
some public and all private recombinant DNA activities are not bound 
to follow any set of safety precautions. 
H.R. 11192 is a 2-year interim control bill which would : 
(1) Require that the sections of the NIH Guidelines, as cur- 
rently amended, on Contaminant (Section II) and Experimental 
Guidelines (Section III) apply to all parties conducting re- 
combinant DNA activities ; 
(2) Empower the Secretary of Health, Education and Wel- 
fare to promulgate administrative regulations, revise the Guide- 
lines to reflect new scientific data, and exempt from the Guide- 
lines activities determined to present no significant risk to health 
or the environment or for specific risk assessment studies ; 
[Appendix B — 190] 
